Malignant
tumors represent some of the most intractable diseases
that endanger human health. A glioma is a tumor of the central nervous
system that is characterized by severe invasiveness, blurred boundaries
between the tumor and surrounding normal tissue, difficult surgical
removal, and high recurrence. Moreover, the blood–brain barrier
(BBB) and multidrug resistance (MDR) are important factors that contribute
to the lack of efficacy of chemotherapy in treating gliomas. A liposome
is a biofilm-like drug delivery system with a unique phospholipid
bilayer that exhibits high affinities with human tissues/organs (e.g.,
BBB). After more than five decades of development, classical and engineered
liposomes consist of four distinct generations, each with different
characteristics: (i) traditional liposomes, (ii) stealth liposomes,
(iii) targeting liposomes, and (iv) biomimetic liposomes, which offer
a promising approach to promote drugs across the BBB and to reverse
MDR. Here, we review the history, preparatory methods, and physicochemical
properties of liposomes. Furthermore, we discuss the mechanisms by
which liposomes have assisted in the diagnosis and treatment of gliomas,
including drug transport across the BBB, inhibition of efflux transporters,
reversal of MDR, and induction of immune responses. Finally, we highlight
ongoing and future clinical trials and applications toward further
developing and testing the efficacies of liposomes in treating gliomas.